Francis Crick, UCL and AZ identify why treatment fails for NSCLC patients
NSCLC accounts for around 85% of all lung cancer cases, particularly in non-smoking patients
Read More
Tag: Tagrisso
AstraZeneca’s Tagrisso delivers positive results
Company’s phase 3 study showed treatment with Tagrisso reduced risk of death by over half
Read More
AZ’ Tagrisso first to win MHRA approval under Project Orbis
Decision brings the innovative treatment to early-stage lung cancer patients, helping to address unmet need in this setting
Read More
Tagrisso moves closer towards EU approval for early-stage lung cancer
Therapy wins a positive CHMP opinion for the adjuvant treatment of early-stage EGFR-mutated NSCLC
Read More
Green light for AZ’s Tagrisso in early-stage lung cancer
EGFR-TKI approved in the US for early non-small cell lung cancer
Read More
AZ’s Tagrisso scores priority review from FDA
Agency will review drug for the treatment of early-stage EGFR-mutated lung cancer
Read More
NICE backing for AZ’ Tagrisso
The Institute has endorsed the drug for first-line treatment of adults with locally-advanced or EGFR mutation-positive NSCLC
Read More
Tagrisso shows ‘unprecedented’ disease free survival in lung cancer
The Phase III ADAURA trial showed treatment with Tagrisso after surgery with curative intent the the risk of disease recurrence or death by around 80%
Read More
Tagrisso hit with NICE rejection for NSCLC
Unfortunately, the drug is not considered eligible for inclusion in the Cancer Drugs Fund either.
Read More
AZ’ Tagrisso improves overall survival in lung cancer
The trial previously met its primary endpoint in July 2017, showing a statistically-significant and clinically-meaningful improvement in progression-free survival.
Read More
AZ to appeal NICE rejection for lung cancer drug
The committee didn’t OK the drug as the cost effectiveness estimates were above what NICE normally considers to be an acceptable use of NHS resources.
Read More
Savolitinib found to help treatment-resistant lung cancer in combo with AZ’s Tagrisso
The news was announced at the American Association for Cancer Research (AACR) annual meeting.
Read More
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
